Sigma Planning’s Kalaris Therapeutics KLRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-10,167
Closed -$41.4K – 1469
2026
Q2
$41.4K Buy
+10,167
New +$52.8K ﹤0.01% 1398

Other funds holding KLRS

Sigma Planning's KLRS Position: Q3 2026 in Review

Sigma Planning sold out of Kalaris Therapeutics (KLRS) in Q3 2026, closing a stake of 10,167 shares — an estimated $41.4K sold.

Sigma Planning first reported a position in KLRS in Q2 2026 and held it in 1 quarter. The position peaked at $41.4K in Q2 2026. 37 funds tracked by Wall St. Rank hold KLRS as of Q3 2026.

  • Sigma Planning reported no remaining Kalaris Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Sigma Planning sold 10,167 Kalaris Therapeutics shares in Q3 2026, an estimated $41.4K.
  • Sigma Planning first reported a position in Kalaris Therapeutics in Q2 2026 and held it in 1 quarter.
  • Sigma Planning's Kalaris Therapeutics position peaked at $41.4K in Q2 2026.
  • 37 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2026.

Based on Sigma Planning's 13F filing for Q3 2026, filed 23 Oct 2026.